表紙
市場調查報告書
商品編碼
661179

全球膀胱過動症(OAB)治療市場 - 成長,趨勢,預測(2019年∼2024年)

Overactive Bladder Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球膀胱過動症(OAB)治療市場,預計從2019年到2024年間,將以2.9%的年複合成長率成長。由於引發膀胱過動症的帕金森氏症等的盛行率上升和高齡化等促進該市場成長。

本報告提供全球膀胱過動症(OAB)市場調查,市場概要,各治療類型、疾病類型、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 高齡化和引發膀胱過動症的疾病的盛行率上升
    • 針對活躍膀胱過動症的醫藥品開發
  • 市場阻礙因素
    • 現行治療的副作用
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 治療各類型
    • 抗膽鹼促效劑
    • Mirabegron
    • 神經刺激療法
    • 膀胱內注射療法
    • 其他
  • 各疾病類型
    • 特發性膀胱過動症
    • 神經性膀胱過動症
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Allergan PLC
    • Astellas Pharma Inc.
    • Cogentix Medical Inc.
    • Endo International PLC
    • 久光製藥
    • Johnson & Johnson
    • Medtronic PLC
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Limited
    • Macleods Pharmaceuticals Ltd

第7章 市場機會及未來趨勢

目錄
Product Code: 61502

The overactive bladder (OAB) treatment market is expected to register a CAGR of 3.4% over the forecast period. The increasing incidence of diseases, such as Parkinson's disease, which leads to overactive bladder disorder, and rising geriatric population, are primary drivers of the global market. In 2017, as per the World Ageing Report, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Urinary incontinence generally increases with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

Key Market Trends

Idiopathic Overactive Bladder Treatment Segment is Expected to Hold a Major Share in the Overactive Bladder Treatment Market

Idiopathic overactive bladder treatment is expected to majorly contribute to the revenues over the forecast period, owing to its high prevalence. Due to the bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. In 2017, as per the National Association for Incontinence, the urinary incontinence affected about 200 million people worldwide. This is expected to encourage key companies to invest in this segment. Increasing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the growing prevalence of the disease with rising age, and the presence of major players, the market is expected to grow during the forecast period. According to the National Association for Incontinence 2020, approximately 25 million adult Americans suffer from some form of urinary incontinence, among them 75-80% are women. Due to the increasing prevalence of bladder over-activity, geriatric population, healthcare expenditure, and awareness about overactive bladder treatments, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.

Competitive Landscape

The overactive bladder treatment market is moderately fragmented, with global pharmaceutical companies controlling significant market share. Moreover, the generic space of the market is observing a trend of consolidation and high competition. Major market players include Allergan PLC, Astellas Pharma Inc., Cogentix Medical Inc., Endo International PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Medtronic PLC, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Limited, and Macleods Pharmaceuticals Ltd, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Aging Population and Increasing Prevalence of Diseases Causing Overactive Bladder
    • 4.2.2 Increasing Trend of Drug Development for Overactive Bladder Treatment
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Current Treatments
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Anticholinergics
    • 5.1.2 Mirabegron
    • 5.1.3 Neurostimulation
    • 5.1.4 Intravesical Instillation
    • 5.1.5 Other Therapies
  • 5.2 By Disease Type
    • 5.2.1 Idiopathic Overactive Bladder
    • 5.2.2 Neurogenic Overactive Bladder
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 Cogentix Medical Inc.
    • 6.1.4 Endo International PLC
    • 6.1.5 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Medtronic PLC
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi
    • 6.1.10 Teva Pharmaceutical Industries Limited
    • 6.1.11 Machloed pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS